Status:
TERMINATED
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Lead Sponsor:
Pfizer
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy o...
Detailed Description
The interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern.
Eligibility Criteria
Inclusion
- Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.
- Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.
- Stroke involving upper extremity.
- Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.
Exclusion
- Any other severe acute or chronic medical or psychiatric condition besides the stroke.
- Women of child bearing potential.
- Uncontrolled hypertension.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT01208233
Start Date
December 1 2010
End Date
December 1 2013
Last Update
February 19 2016
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Spain Rehabilitation Center
Birmingham, Alabama, United States, 35233
2
The Kirklin Clinic
Birmingham, Alabama, United States, 35233
3
University Hospital
Birmingham, Alabama, United States, 35294-3280
4
Broward Health North
Deerfield Beach, Florida, United States, 33064